Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2018

01-03-2018 | Review Article

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group

Authors: Paola Perego, Georg Hempel, Stig Linder, Tracey D. Bradshaw, Annette K. Larsen, Godefridus J. Peters, Roger M. Phillips, On behalf of the EORTC PAMM Group

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Login to get access

Abstract

An increasing number of manuscripts focus on the in vitro evaluation of established and novel anti-tumor agents in experimental models. Whilst the design of such in vitro assays is inherently flexible, some of these studies lack the minimum information necessary to critically evaluate their relevance or have been carried out under unsuitable conditions. The use of appropriate and robust methods and experimental design has important implications for generating results that are reliable, relevant, and reproducible. The Pharmacology and Molecular Mechanisms (PAMM) group of the European Organization for Research and Treatment of Cancer (EORTC) is the largest group of academic scientists working on drug development and bundle decades of expertise in this field. This position paper addresses all researchers with an interest in the preclinical and cellular pharmacology of anti-tumor agents and aims at generating basic recommendations for the correct use of compounds to be tested for anti-tumor activity using a range of preclinical cellular models of cancer.
Literature
1.
Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, Kroemer G (2008) Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 27:4221–4232CrossRefPubMed
2.
Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G, Del Sal G (2004) Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 14:625–636CrossRefPubMed
3.
Hendriks HR, Govaerts AS, Fichtner I, Burtles S, Westwell AD, Peters GJ (2017) Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative. Br J Cancer 117:195–202CrossRefPubMed
4.
Righetti SC, Perego P, Carenini N, Zunino F (2008) Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells. Cancer Lett 263:140–144CrossRefPubMed
5.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319CrossRefPubMed
6.
Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601PubMed
7.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112CrossRefPubMed
8.
9.
Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727–741CrossRefPubMed
10.
Rossi C, Gasparini G, Canobbio L, Galligioni E, Volpe R, Candiani E, Toffoli G, D’Incalci M (1987) Doxorubicin distribution in human breast cancer. Cancer Treat Rep 71:1221–1226PubMed
11.
12.
Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276CrossRefPubMed
13.
Lanvers C, Hempel G, Blaschke G, Boos J (1998) Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells. FASEB J 12:1627–1633CrossRefPubMed
14.
Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A (2016) Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget 7:38467–38486CrossRefPubMedPubMedCentral
15.
Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17:7337–7346CrossRefPubMedPubMedCentral
16.
Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, Verheul HM (2014) Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience 1:844–853CrossRefPubMedPubMedCentral
17.
Peters GJ, Lankelma J, Kok RM, Noordhuis P, van Groeningen CJ, van der Wilt CL, Meyer S, Pinedo HM (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 31:269–276CrossRefPubMed
18.
Da Silva CG, Honeywell RJ, Dekker H, Peters GJ (2015) Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. Expert Opin Drug Metab Toxicol 11:703–717CrossRefPubMed
19.
van der Veldt AA, Smit EF, Lammertsma AA (2013) Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [(11)C]docetaxel. Front Oncol 3:208PubMedPubMedCentral
20.
Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DA, Postmus PE, Lammertsma AA, Hendrikse NH (2013) Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res 19:183–193CrossRefPubMed
21.
Qazzaz ME, Raja VJ, Lim KH, Kam TS, Lee JB, Gershkovich P, Bradshaw TD (2016) In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B. Cancer Lett 370:185–197CrossRefPubMed
22.
Stone EL, Citossi F, Singh R, Kaur B, Gaskell M, Farmer PB, Monks A, Hose C, Stevens MF, Leong CO, Stocks M, Kellam B, Marlow M, Bradshaw TD (2015) Antitumour benzothiazoles. Part 32: DNA adducts and double strand breaks correlate with activity; synthesis of 5F203 hydrogels for local delivery. Bioorg Med Chem 23:6891–6899CrossRefPubMed
23.
Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120:175–180CrossRefPubMed
24.
Akpinar B, Bracht EV, Reijnders D, Safarikova B, Jelinkova I, Grandien A, Vaculova AH, Zhivotovsky B, Olsson M (2015) 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53. Oncotarget 6:43679–43697CrossRefPubMedPubMedCentral
25.
van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, Wattel E, Peters GJ, Lankelma J (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48:6956–6961PubMed
26.
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664CrossRefPubMed
27.
van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, Vermorken JB, van Groeningen CJ, van der Vijgh WJ, Peters GJ (1999) Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 10:441–448CrossRefPubMed
28.
Vanarkotte J, Peters G, Pizao P, Keepers Y, Giaccone G (1994) In-vitro schedule-dependency of eo9 and miltefosine in comparison to standard drugs in colon-cancer cells. Int J Oncol 4:709–715PubMed
29.
Lee LF, Li G, Templeton DJ, Ting JP (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253–28260CrossRefPubMed
30.
Borst P, Borst J, Smets LA (2001) Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist Updat 4:129–131CrossRefPubMed
31.
Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231–237CrossRefPubMed
32.
Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC, Linder S (2007) Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an “off-target” effect? Mini Rev Med Chem 7:1035–1039CrossRefPubMed
33.
Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB (2004) Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18:1272–1282CrossRefPubMedPubMedCentral
34.
Borst P, Rottenberg S (2004) Cancer cell death by programmed necrosis? Drug Resist Updat 7:321–324CrossRefPubMed
35.
Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657–663CrossRefPubMed
36.
Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ (1998) Cisplatin binding sites on human albumin. J Biol Chem 273:14721–14730CrossRefPubMed
37.
Faulkner AD, Kaner RA, Abdallah QM, Clarkson G, Fox DJ, Gurnani P, Howson SE, Phillips RM, Roper DI, Simpson DH, Scott P (2014) Asymmetric triplex metallohelices with high and selective activity against cancer cells. Nat Chem 6:797–803CrossRefPubMed
38.
Kaner RA, Allison SJ, Faulkner AD, Phillips RM, Roper DI, Shepherd SL, Simpson DH, Waterfield NR, Scott P (2016) Anticancer metallohelices: nanomolar potency and high selectivity. Chem Sci 7:951–958CrossRefPubMed
39.
Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM (2014) Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res 74:3913–3922CrossRefPubMedPubMedCentral
40.
Sundquist WI, Lippard SJ, Stollar BD (1987) Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). Proc Natl Acad Sci USA 84:8225–8229CrossRefPubMedPubMedCentral
41.
Fischer SJ, Benson LM, Fauq A, Naylor S, Windebank AJ (2008) Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. Neurotoxicology 29:444–452CrossRefPubMed
42.
Zheng H, Fink D, Howell SB (1997) Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin. Clin Cancer Res 3:1157–1165PubMed
43.
Honeywell RJ, Fatmawati C, Buddha M, Hitzerd S, Kathman I, Peters GJ (2015) Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors. ADMET DMPK 3:51–67CrossRef
44.
Wagner A, Hempel G, Gumbinger HG, Jurgens H, Boos J (1999) Pharmacokinetics of anticancer drugs in vitro. Adv Exp Med Biol 457:397–407CrossRefPubMed
45.
Jacobson PA, Green K, Birnbaum A, Remmel RP (2002) Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 49:461–467CrossRefPubMed
46.
Phillips RM, Bibby MC, Double JA (1988) Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemother Pharmacol 21:168–172CrossRefPubMed
47.
Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841–1851CrossRefPubMed
48.
Perego P, Robert J (2016) Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol 77:5–18CrossRefPubMed
49.
Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6:638–647CrossRefPubMed
50.
Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78:661–671CrossRefPubMed
51.
Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A (2017) Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol 43:119–133CrossRefPubMed
52.
53.
Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM (2008) Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 453:940–943CrossRefPubMed
54.
55.
Oudin MJ, Weaver VM (2016) Physical and chemical gradients in the tumor microenvironment regulate tumor cell invasion, migration, and metastasis. Cold Spring Harb Symp Quant Biol 81:189–205CrossRefPubMed
56.
Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba Y (2013) Acidic extracellular microenvironment and cancer. Cancer Cell Int 13:89–2867-13-89CrossRefPubMedPubMedCentral
57.
Swietach P, Vaughan-Jones RD, Harris AL, Hulikova A (2014) The chemistry, physiology and pathology of pH in cancer. Philos Trans R Soc Lond B Biol Sci 369:20130099CrossRefPubMedPubMedCentral
58.
Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217–229CrossRefPubMed
59.
Valko KL, Teague SP, Pidgeon C (2017) In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery. ADMET DMPK 5:14–38CrossRef
60.
61.
62.
Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, Brennan P, Fegan C, Wang S, Pepper C (2014) A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 5:375–385CrossRefPubMed
63.
64.
Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284CrossRefPubMed
65.
Dalerba P, Clarke MF (2007) Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1:241–242CrossRefPubMed
66.
Freshney RI (2016) Culture of animal cells: a manual of basic technique and specialized applications, 7th edn, Wiley-Blackwell
67.
Collins L, Franzblau SG (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41:1004–1009PubMedPubMedCentral
68.
69.
van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM, Peters GJ (2000) Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta 1474:5–12CrossRefPubMed
70.
Fayad W, Brnjic S, Berglind D, Blixt S, Shoshan MC, Berndtsson M, Olofsson MH, Linder S (2009) Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer 125:2450–2455CrossRefPubMed
71.
Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK (2003) Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 83:173–180CrossRefPubMed
72.
Padron JM, van der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HH, Pizao PE, Giaccone G, Peters GJ (2000) The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 36:141–157CrossRefPubMed
73.
Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D (1979) Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 5:1225–1230CrossRefPubMed
74.
Olive PL, Durand RE (1994) Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev 13:121–138CrossRefPubMed
75.
Frankel A, Buckman R, Kerbel RS (1997) Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57:2388–2393PubMed
76.
D’Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D’Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, Cappuzzo F (2015) Cancer stem cells sensitivity assay (STELLA) in patients with advanced lung and colorectal cancer: a feasibility study. PLoS One 10:e0125037CrossRefPubMedPubMedCentral
77.
Beretta GL, De Cesare M, Albano L, Magnifico A, Carenini N, Corna E, Perego P, Gatti L (2016) Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness. Tumori 102:144–149CrossRefPubMed
78.
Drost J, Clevers H (2017) Translational applications of adult stem cell-derived organoids. Development 144:968–975CrossRefPubMed
79.
Phillips RM, Loadman PM, Cronin BP (1998) Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 77:2112–2119CrossRefPubMedPubMedCentral
80.
Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR (2003) Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 63:5970–5977PubMed
81.
Foehrenbacher A, Secomb TW, Wilson WR, Hicks KO (2013) Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. Front Oncol 3:314PubMedPubMedCentral
82.
Groh CM, Hubbard ME, Jones PF, Loadman PM, Periasamy N, Sleeman BD, Smye SW, Twelves CJ, Phillips RM (2014) Mathematical and computational models of drug transport in tumours. J R Soc Interface 11:20131173CrossRefPubMedPubMedCentral
83.
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70:440–446CrossRefPubMed
84.
Bijnsdorp IV, Giovannetti E, Peters GJ (2011) Analysis of drug interactions. Methods Mol Biol 731:421–434CrossRefPubMed
85.
Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227–253CrossRefPubMed
86.
Kern DH, Morgan CR, Hildebrand-Zanki SU (1988) In vitro pharmacodynamics of 1-beta-d-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res 48:117–121PubMed
87.
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed
88.
Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, Johnston SE, Vrcic A, Wong B, Khan M, Asiedu J, Narayan R, Mader CC, Subramanian A, Golub TR (2017) The drug repurposing hub: a next-generation drug library and information resource. Nat Med 23:405–408CrossRefPubMedPubMedCentral
89.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMed
90.
Eastman A (2017) Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. Oncotarget 8:8854–8866CrossRefPubMed
91.
Metadata
Title
Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
Authors
Paola Perego
Georg Hempel
Stig Linder
Tracey D. Bradshaw
Annette K. Larsen
Godefridus J. Peters
Roger M. Phillips
On behalf of the EORTC PAMM Group
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3502-7

Other articles of this Issue 3/2018

Cancer Chemotherapy and Pharmacology 3/2018 Go to the issue

Original Article

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies

Short Communication

Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs

Original Article

Pharmacokinetics of dacarbazine (DTIC) in pregnancy

Original Article

The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer

Original Article

Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors

Review Article

First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits